摘要: High-level aminoglycoside resistance in enterococci is mediated generally by aminoglycoside-modifying enzymes, which eliminate the synergistic bactericidal effect usually seen when a cell wall-active agent combined with an aminoglycoside. Clinical microbiology laboratories currently screen for testing gentamicin and streptomycin susceptibility. If recently detected genes, aph(2")-Ib, aph(2")-Ic, aph(2")-Id, become more prevalent among clinical isolates, approach detecting susceptibility to synergism will require modification. More potent aminoglycosides need be developed that resistant modification broad spectrum of enzymes present enterococci.